Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack Cuzick

Showing results (111-120 of 421) with videos related to

Pageof 43
Sort By:
The Cochrane Database of Systematic Reviews|October 26, 2021
Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker reviewEmma C Atakpa, Mangesh A Thorat, Jack Cuzick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2017
Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I)Samuel George Smith, Ivana Sestak, Anthony Howell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2015
Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention TrialFrancesco Spagnolo, Ivana Sestak, Anthony Howell, et al.
International Journal of Cancer|July 24, 2009
How to evaluate emerging technologies in cervical cancer screening?Marc Arbyn, Guglielmo Ronco, Jack Cuzick, et al.
American Journal of Obstetrics and Gynecology|November 21, 2008
A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trialSean R Duffy, Wolfgang Distler, Anthony Howell, et al.
Advances in Experimental Medicine and Biology|May 24, 2008
Response and resistance to the endocrine prevention of breast cancerAnthony Howell, Nigel J Bundred, Jack Cuzick, et al.
Journal of Medical Screening|December 15, 2007
Surrogate endpoints for cancer screening trials: general principles and an illustration using the UK Flexible Sigmoidoscopy Screening TrialJack Cuzick, Fay H Cafferty, Robert Edwards, et al.
BMC Cancer|January 17, 2007
Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based studyRahul Roychoudhuri, David Robinson, Venkata Putcha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2005
Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating studyMitch Dowsett, Jack Cuzick, Chris Wale, et al.
Breast Cancer Research and Treatment|September 1, 2006
Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancerDavid Cella, Lesley Fallowfield, Peter Barker, et al.
Pageof 43

Showing results (111-120 of 421) with videos related to

Sort By:
Pageof 43
The Cochrane Database of Systematic Reviews|October 26, 2021
Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker reviewEmma C Atakpa, Mangesh A Thorat, Jack Cuzick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2017
Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I)Samuel George Smith, Ivana Sestak, Anthony Howell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2015
Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention TrialFrancesco Spagnolo, Ivana Sestak, Anthony Howell, et al.
International Journal of Cancer|July 24, 2009
How to evaluate emerging technologies in cervical cancer screening?Marc Arbyn, Guglielmo Ronco, Jack Cuzick, et al.
American Journal of Obstetrics and Gynecology|November 21, 2008
A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trialSean R Duffy, Wolfgang Distler, Anthony Howell, et al.
Advances in Experimental Medicine and Biology|May 24, 2008
Response and resistance to the endocrine prevention of breast cancerAnthony Howell, Nigel J Bundred, Jack Cuzick, et al.
Journal of Medical Screening|December 15, 2007
Surrogate endpoints for cancer screening trials: general principles and an illustration using the UK Flexible Sigmoidoscopy Screening TrialJack Cuzick, Fay H Cafferty, Robert Edwards, et al.
BMC Cancer|January 17, 2007
Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based studyRahul Roychoudhuri, David Robinson, Venkata Putcha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2005
Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating studyMitch Dowsett, Jack Cuzick, Chris Wale, et al.
Breast Cancer Research and Treatment|September 1, 2006
Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancerDavid Cella, Lesley Fallowfield, Peter Barker, et al.
Pageof 43